Myron Z. Holubiak - Jul 22, 2021 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Alexander M. Donaldson, by power of attorney
Stock symbol
CTXR
Transactions as of
Jul 22, 2021
Transactions value $
$0
Form type
4
Date filed
7/26/2021, 05:02 PM
Previous filing
May 24, 2021
Next filing
Oct 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTXR Common Stock 1.99M Jul 22, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTXR Options to Purchase Common Stock Award $0 +300K $0.00 300K Jul 22, 2021 Common Stock 300K $2.00 Direct F8
transaction CTXR Options to Purchase Common Stock Award $0 +10K $0.00 10K Jul 22, 2021 Common Stock 10K $2.00 See Footnote F8, F9
holding CTXR Warrant to Purchase Common Stock 784K Jul 22, 2021 Common Stock 784K $1.15 Direct F1, F2
holding CTXR Options to Purchase Common Stock 26.7K Jul 22, 2021 Common Stock 26.7K $8.10 Direct F3
holding CTXR Options to Purchase Common Stock 40K Jul 22, 2021 Common Stock 40K $3.45 Direct F4
holding CTXR Options to Purchase Common Stock 150K Jul 22, 2021 Common Stock 150K $1.62 Direct F5
holding CTXR Warrant to Purchase Common Stock 129K Jul 22, 2021 Common Stock 129K $1.42 Direct F1, F2
holding CTXR Warrant to Purchase Common Stock 559K Jul 22, 2021 Common Stock 559K $0.77 Direct F1, F2
holding CTXR Options to Purchase Common Stock 175K Jul 22, 2021 Common Stock 175K $0.67 Direct F6
holding CTXR Options to Purchase Common Stock 200K Jul 22, 2021 Common Stock 200K $1.01 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The warrant is fully vested and exercisable immediately.
F2 The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
F3 The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.
F4 One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest.
F5 One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.
F6 The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F7 The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F8 The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F9 The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.